Compare SACH & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SACH | PRPO |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.4M | 40.1M |
| IPO Year | 2016 | 2000 |
| Metric | SACH | PRPO |
|---|---|---|
| Price | $0.80 | $22.71 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 104.9K | 100.4K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 19.23% | N/A |
| EPS Growth | ★ 104.30 | 92.15 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $57,500,000.00 | $24,049,000.00 |
| Revenue This Year | $145.00 | N/A |
| Revenue Next Year | $6.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $0.77 | $13.80 |
| 52 Week High | $1.45 | $33.63 |
| Indicator | SACH | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 37.95 | 47.87 |
| Support Level | $0.77 | $22.13 |
| Resistance Level | $0.87 | $25.27 |
| Average True Range (ATR) | 0.03 | 1.55 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 26.30 | 62.20 |
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns the majority of its revenue through Interest income from loans.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.